AMSBIO reports on a recent published paper** by the Howard Hughes Medical Institute at the Massachusetts Institute of Technology (MIT) investigating why epithelial cells grown in monolayers on a plastic dish are worse at segregating their chromosomes than epithelial cells in vivo or in 3D organoid cultures.
News
We are happy to announce the below adversting offer from New Scientist for our members.
Individual Advertising
Standard Branded Advert - £299 (reduced from £599)
• Advert branded with logo live for up to 28 days
Demonstrating continuing support for immuno-oncology researchers, BioIVT extends excellence in research to help researchers screen novel therapeutics
Plant-expression deal for difficult to produce proteins, vaccines, metabolites and natural proteins
29 May 2019: Norwich, UK Leaf Expression Systems, a contract development and manufacturing organisation specialising in the plant-based expression and production of proteins, vaccines, metabolites and complex natural proteins, has announced the launch of its online list of products available for purchase by researchers working within the life sciences and agricultural industries.
Following the continued success of Pharma Integrates, the inaugural Bio Integrates event took place on 22nd May in London. The sold-out conference hosted 315 delegates from across biotech, pharma, investment, charities and patient groups.
AMSBIO introduces StemFit® Basic04, a next generation feeder-free medium for the maintenance of Induced Pluripotent Stem (iPS) and Embryonic Stem (ES) cells during the reprogramming, expansion and differentiation phases of stem cell culture. With its fully defined and animal-origin free formulation, StemFit® Basic04 is suited to both research studies and translation to cell therapy.
SOMERSET, N.J. – May 23, 2019 — Catalent (Booth 3101), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, is to launch its new OneBio SuiteSM for the integrated development, manufacturing, and clinical supply of biologic drugs at the BIO International Convention, which takes place at the Pennsylvania Convention Center in Philadelphia, from June 3-6, 2019.
The word “undruggable” has hampered pursuit of the most compelling biological targets, drawing from established opinion that pharmacological modulation was not possible. Scientists at Dogma Therapeutics (“Dogma”) were determined to challenge this assumption. Dogma has discovered an orally-bioavailable small molecule PCSK9 inhibitor. By strategically focusing on small molecule inhibitors, Dogma can readily combine their compounds with current standard of care and dramatically disrupt the health economics of PCSK9-based therapies.
Coventry, UK, 21st May 2019 / Medherant Limited (“Medherant”), the clinical-stage developer of innovative transdermal delivery products for pain and CNS diseases using its unique TEPI Patch® technology, has today announced a new £2 million investment. The additional funding from Mercia Technologies PLC, the national investment group focused on the identification, creation, funding and scaling of innovative technology businesses with high growth potential, is part of a circa £2.4 million syndicated investment round.